Atara Biotherapeutics Inc. (ATRA)

35.9 +0.85 (+2.425%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 35.05

Price Open 35.05

Volume: 847,540

Avg Volume: 442,840

Market Cap: 1.63B

P/E Ratio -8.22

52 Wk Range 12.65-54.45



ATRA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
43.31M
6.79M
17.05
15.69%

2018-07-13
41.92M
6.7M
10.21
15.99%

2018-06-29
41.92M
7.13M
10.05
17.00%

2018-06-15
41.93M
6.7M
11.20
15.99%




ATRA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-01
Q2 2018
N/A
-0.97 (3)
-1.15
-0.18

2018-05-08
Q1 2018
N/A
-0.93 (3)
-1.05
-0.12

2018-05-03
Q1 2018
N/A
-0.91 (2)
0.00
0.00

2018-03-08
Q4 2017
N/A
-1.14 (2)
0.00
0.00

News

Bulletproof Investing Performance Update: Week 38 (2018-08-16 16:05 SeekingAlpha)

Safety first: Sprint car driver McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 38 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This…

 


Statistics

Shares Outstanding: 45.34M

Top 15 Institution Percent: N/A

Price To Sales: N/A

Price To Book: 3.60

Revenue: N/A

Gross Profit: N/A

Cash: 200.22M

Debt: N/A

Return On Assets: -43.08

Return On Equity: -47.13

Profit Margin: N/A

Price History

Beta: 2.53

50-day Moving Avg: 39.86

200-day Moving Avg: 34.27

YTD Change: 98.34

5-day Change: -5.03

1-month Change: -11.36

3-month Change: -25.05

6-month Change: -19.87

1-year Change: 163.00

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Atara Biotherapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.atarabio.com

Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.